Navigation Links
Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
Date:10/27/2011

uch as decreased hemoglobin, fatigue, and osteoporosis.

About Regeneron PharmaceuticalsRegeneron is a fully integrated biopharmaceutical company that discovers, develops, manufacturers, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, which is approved for the treatment of a rare inflammatory condition, Regeneron has completed Phase 3 clinical trials of rilonacept for a new indication and of product candidates EYLEA™ (aflibercept injection; VEGF Trap-Eye) in diseases of the eye, and ZALTRAP® (aflibercept;VEGF Trap) in colorectal cancer.  EYLEA is currently under review with U.S. and European regulatory authorities.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on www.regeneron.com

Forward Looking StatementsThis news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future financial performance of Regeneron, and actual events or results may differ materially from these forward-looking statements.  These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's product candidates and research and clinical programs now underway or planned, the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to devel
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmaxis Announces Major Milestone: Positive Bronchitol Opinion for Europe
2. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
3. Hydrocodone and Oxycodones Lead U.S. General Workforce Positives, Outranked Only by Marijuana, According to Quest Diagnostics Drug Testing Index™
4. Hepatitis C Phase 2A Trial Positive Results
5. Daval International Announces Positive Phase II Results for AIMSPRO® as a Monotherapy in Established Diffuse Cutaneous Systemic Sclerosis (Scleroderma)
6. Echo Therapeutics Announces Positive Results of Clinical Trial of Its Symphony® Continuous Glucose Monitoring System
7. NVA237 Filed in Europe and Positive Phase III Data at European Respiratory Society Congress
8. Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials
9. Ampio Announces Positive Results From 12-Week Open Label Extension Study of Zertane™ in Patients With Premature Ejaculation.
10. ALIMTA Receives Positive Opinion From CHMP as Continuation Maintenance Therapy for Deadly Form of Lung Cancer
11. Clermont Pharmaceuticals Reports Positive Phase III Results for Drug to Treat Glaucoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... -- ConvaTec, a privately-held medical products and technologies company, today ... Executive Officer of the company, effective December 22, 2014. ... "The Board of Directors of ConvaTec thanks Mr. Berger ... three years," said Magnus Lundberg , the Chairman ... the company is well positioned for the future."  The ...
(Date:12/22/2014)... Mass , Dec. 22, 2014 /PRNewswire/ -- RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today issued the following open letter ... Cauwenbergh , Dr. Med. Sc. Dear ... days a number of inaccurate statements posted on ...
(Date:12/22/2014)... 22, 2014  Pfenex Inc. (NYSE MKT: PFNX) today ... has been filed and is now open and that ... Department of Health and Human Services (HHS), through the ... "We are extremely pleased to have the IND now ... a significant milestone in our company,s partnership with BARDA ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), ... today announced the appointment of Wendy Dixon , ... 30 years of pharmaceutical development and commercial experience to ... product launches and portfolio evaluation in cardiometabolic and primary ...
... , MADRID , April 21 PharmaMar, ... with marine-based anti-tumor drugs Yondelis(R), Zalypsis(R) and Irvalec(R) at the American Association ... from April 17-21 . , ... The AACR meeting is the leading convention on cancer research, ...
Cached Medicine Technology:Orexigen(R) Therapeutics Appoints Wendy Dixon, Ph.D. to Board of Directors 2Orexigen(R) Therapeutics Appoints Wendy Dixon, Ph.D. to Board of Directors 3PharmaMar Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention 2PharmaMar Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention 3
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, BellasDress has launched ... wedding dresses. BellasDress has chosen their best-selling lace wedding ... for the holiday season. , Now, BellasDress.com features ... gowns here at discount prices. The business hopes everyone ... website. , “All our elegant products are ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... children with complex chronic illnesses can receive effective, less expensive ... with easy access to a team of dedicated health care ... to become seriously ill and need either hospitalization or a ... an enhanced medical home clinic at the University of Texas ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 AngelWeddingDress.com tries ... to the online realm. Today, the business has introduced ... a site-wide prom dress promotion. , The new prom ... each and every dress lover. They are specially designed ... 2015 prom dresses should visit its website before ...
(Date:12/25/2014)... Each year trauma accounts for approximately 42 ... across the nation (according to the Centers for ... Hospital Ambulatory Medical Care Survey collected data from ... They estimated that there were between 3.5 and 4.4 ... diagnosis of broken bone or fracture. , When ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4
... , THURSDAY, Sept. 23 (HealthDay News) -- Distracted driving fatalities ... space of three years, according to new U.S. government research ... in car accidents from 2001 to 2007, the researchers estimated. ... rose 28 percent in just three years, from 4,572 in ...
... Bloomberg Faculty of Nursing professor, Dr. Diane Doran, was ... help protect the safety of over 900,000 Canadians who ... The Canadian Patient Safety Institute and its partners ... competition drawing some of Canada,s leading healthcare researchers. The ...
... Gordon HealthDay Reporter , THURSDAY, Sept. 23 (HealthDay ... was living his boyhood dream. He,d just been plucked ... on the courts of the National Basketball Association,s Dallas Mavericks, ... a local tournament. But a small on-court collision with ...
... A concerted effort to boost research on women,s health over ... and reduced deaths among women due to cardiovascular disease, breast ... Institute of Medicine. The effort has yielded less but ... and osteoporosis on women, added the committee that wrote the ...
... the University of California, San Diego School of Medicine ... UCSD Cancer Center, has been named the 2010 recipient ... the Metastasis Research Society, an international, non-profit organization that ... at a recent joint meeting of the MRS and ...
... Estonia (September 23, 2010) At an international gathering of ... Vaccine Foundation announced it will initiate a clinical trial of ... researchers at Saint Louis University in St. Louis, Missouri, USA. ... on TB Vaccine Development. Building on more than ...
Cached Medicine News:Health News:Texting Taking a Deadly Toll on Roads 2Health News:Texting Taking a Deadly Toll on Roads 3Health News:$1 million awarded to Bloomberg Faculty of Nursing-led research team 2Health News:Experimental Leukemia Drug Proves a Slam Dunk 2Health News:Experimental Leukemia Drug Proves a Slam Dunk 3Health News:Experimental Leukemia Drug Proves a Slam Dunk 4Health News:Increased attention to women's health research has yielded gains on some important conditions, but progress lags on others 2Health News:Increased attention to women's health research has yielded gains on some important conditions, but progress lags on others 3Health News:David Cheresh receives top award for cancer metastasis research 2Health News:New TB vaccine enters clinical testing 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: